ImmunityBio (IBRX) Stock Highlights

2.62 | -1.87%

2024-12-21 02:36:56

ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The companys immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term immunological memory.

Statistics

Range Today

2.61 2.71

Volume Today 7.87M

Range 1 Year

2.61 10.53

Volume 1 Year 1.27B

Range 3 Year

1.21 10.53

Volume 3 Year 2.75B

Range 10 Year

0.93 45.42

Volume 10 Year 3.95B

Highlights

Market Capitalization 3.88B (mid)

Floating Shares 165.47M

Current Price 2.62

Price To Earnings -5.47

Price To Revenue 3.42K

Earnings Per Share -0.96

Payout Ratio 0%

Performance

Latest -1.87%

1 Month -50.75%

3 Months -24.71%

6 Months -59.25%

1 Year -38.35%

3 Years -60.54%

5 Years -26.82%

10 Years -92.92%

Benchmarks

Market Capitalization

58 / 368

Gross Profits

140 / 278

Total Revenue

249 / 300

Total Rank

324 / 368

Free Cashflow

331 / 352

Performance 5 years

143 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.